Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (735) 735
Book Review (68) 68
Patent (48) 48
Publication (28) 28
Conference Proceeding (24) 24
Book Chapter (10) 10
Dissertation (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (411) 411
humans (405) 405
gastroenterology & hepatology (277) 277
male (260) 260
female (257) 257
adult (238) 238
middle aged (226) 226
antiviral agents - therapeutic use (166) 166
treatment outcome (111) 111
drug therapy, combination (110) 110
hepatitis c, chronic - drug therapy (110) 110
interferon-alpha - therapeutic use (106) 106
aged (103) 103
hepatitis c (103) 103
therapy (101) 101
hepacivirus - genetics (99) 99
gastroenterology and hepatology (97) 97
genotype (97) 97
hepatitis c virus (93) 93
hepatitis b, chronic - drug therapy (89) 89
interferon (89) 89
hepatitis b (87) 87
recombinant proteins (86) 86
abridged index medicus (84) 84
hepatitis (82) 82
ribavirin (81) 81
cirrhosis (72) 72
virus-infection (72) 72
hepatitis c, chronic - virology (68) 68
health aspects (63) 63
antiviral agents - administration & dosage (62) 62
hepatitis b virus - genetics (62) 62
polyethylene glycols - therapeutic use (62) 62
ribavirin - therapeutic use (61) 61
rna, viral - blood (60) 60
alanine transaminase - blood (56) 56
antiviral agents - adverse effects (56) 56
viral load (56) 56
infection (54) 54
liver (54) 54
lamivudine (53) 53
liver - pathology (51) 51
adolescent (49) 49
dna, viral - blood (49) 49
care and treatment (46) 46
drug therapy (46) 46
fibrosis (46) 46
prospective studies (46) 46
interferon-alpha - administration & dosage (44) 44
life sciences (43) 43
adenine - analogs & derivatives (41) 41
antiviral agents (41) 41
hepacivirus - drug effects (40) 40
microbiology (40) 40
peginterferon alpha-2a (40) 40
retrospective studies (40) 40
adefovir dipivoxil (39) 39
hepatocellular-carcinoma (39) 39
infectious diseases (39) 39
sustained virological response (39) 39
virus (39) 39
biological response modifiers (38) 38
chemistry (38) 38
hepatitis b e antigens - blood (38) 38
hepatitis c - drug therapy (38) 38
hepatology (38) 38
pegylated interferon (38) 38
ribavirin - administration & dosage (38) 38
time factors (38) 38
interferon-alpha - adverse effects (37) 37
liver cirrhosis - virology (37) 37
analysis (36) 36
hepatitis b, chronic - virology (36) 36
liver cirrhosis (36) 36
metallurgy (36) 36
biochemistry (35) 35
disease (35) 35
double-blind method (35) 35
hepatitis b virus - drug effects (35) 35
hepatitis c, chronic - complications (35) 35
hepatitis c, chronic - pathology (35) 35
polyethylene glycols - administration & dosage (35) 35
young adult (35) 35
adenine - therapeutic use (34) 34
follow-up studies (34) 34
hepatitis b virus (34) 34
prognosis (34) 34
virology (34) 34
chronic hepatitis-c (33) 33
medicine, general & internal (33) 33
natural-history (33) 33
recombinant proteins - therapeutic use (33) 33
enzymology (32) 32
genetic aspects (32) 32
tenofovir (32) 32
beer (31) 31
biopsy (31) 31
compositions or test papers therefor (31) 31
condition-responsive control in microbiological orenzymological processes (31) 31
disease progression (31) 31
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (727) 727
French (85) 85
German (10) 10
Korean (7) 7
Danish (1) 1
Norwegian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
by Marcellin, Patrick, Prof and Gane, Edward, Prof and Buti, Maria, Prof and Afdhal, Nezam, Prof and Sievert, William, Prof and Jacobson, Ira M, Prof and Washington, Mary Kay, Prof and Germanidis, George, Prof and Flaherty, John F, PharmD and Schall, Raul Aguilar, PhD and Bornstein, Jeffrey D, MD and Kitrinos, Kathryn M, PhD and Subramanian, G Mani, MD and McHutchison, John G, MD and Heathcote, E Jenny, Prof
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9865, pp. 468 - 475
Summary Background Whether long-term suppression of replication of hepatitis B virus (HBV) has any beneficial effect on regression of advanced liver fibrosis... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | ADEFOVIR DIPIVOXIL | LIVER FIBROSIS | RISK | REVERSIBILITY | LEVEL | DNA LEVELS | Immunohistochemistry | Severity of Illness Index | Adenine - analogs & derivatives | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Safety Management | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - administration & dosage | Dose-Response Relationship, Drug | Tenofovir | Hepatitis B virus - drug effects | Organophosphonates - administration & dosage | Hepatitis B, Chronic - drug therapy | Time Factors | Adult | Female | Biopsy, Needle | Hepatitis B, Chronic - pathology | Complications and side effects | Dosage and administration | Research | Drug therapy | Liver cirrhosis | Risk factors | Hepatitis B | Hepatitis | Liver cancer | Consent | Mortality | Infections | Histology | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
by Hézode, Christophe, Dr Prof and Asselah, Tarik, Prof and Reddy, K Rajender, Prof and Hassanein, Tarek, Prof and Berenguer, Marina, MD and Fleischer-Stepniewska, Katarzyna, MD and Marcellin, Patrick, Prof and Hall, Coleen, MS and Schnell, Gretja, PhD and Pilot-Matias, Tami, PhD and Mobashery, Niloufar, MD and Redman, Rebecca, MD and Vilchez, Regis A, MD and Pol, Stanislas, Prof
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Summary Background Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | DASABUVIR | SOFOSBUVIR | HCV | INHIBITOR | LEDIPASVIR | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Treatment Outcome | Carbamates - administration & dosage | Hepatitis C, Chronic - drug therapy | Aspartate Aminotransferases - drug effects | Young Adult | Alanine Transaminase - drug effects | Anilides - administration & dosage | Hepatitis C, Chronic - enzymology | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Macrocyclic Compounds - administration & dosage | Drug Therapy, Combination | Virus diseases | Care and treatment | Protease inhibitors | Proteases | Liver | Biological response modifiers | Hepatitis C virus | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Drug therapy | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
by Manns, Michael, Prof and Marcellin, Patrick, Prof and Poordad, Fred, Prof and de Araujo, Evaldo Stanislau Affonso, PhD and Buti, Maria, Prof and Horsmans, Yves, Prof and Janczewska, Ewa, MD and Villamil, Federico, Prof and Scott, Jane, PhD and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Summary Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus... 
Internal Medicine | SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | IN-VITRO | TELAPREVIR | METAANALYSIS | PEGINTERFERON ALPHA-2B | TRIPLE THERAPY | BOCEPREVIR | ONE PILL | CHRONIC HCV INFECTION | ONCE-DAILY TMC435 | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
by Manns, Michael, Prof and Pol, Stanislas, Prof and Jacobson, Ira M, Prof and Marcellin, Patrick, Prof and Gordon, Stuart C, Prof and Peng, Cheng-Yuan, MD and Chang, Ting-Tsung, Prof and Everson, Gregory T, Prof and Heo, Jeong, Prof and Gerken, Guido, Prof and Yoffe, Boris, Prof and Towner, William J, MD and Bourliere, Marc, MD and Metivier, Sophie, MD and Chu, Chi-Jen, MD and Sievert, William, Prof and Bronowicki, Jean-Pierre, Prof and Thabut, Dominique, Prof and Lee, Youn-Jae, Prof and Kao, Jia-Horng, Prof and McPhee, Fiona, PhD and Kopit, Justin, PhD and Mendez, Patricia, MD and Linaberry, Misti, MPH and Hughes, Eric, MD and Noviello, Stephanie, MD and HALLMARK-DUAL Study Team
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9954, pp. 1597 - 1605
Summary Background An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we... 
Internal Medicine | PROTEASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MANAGEMENT | DASABUVIR | SOFOSBUVIR | HCV | THERAPIES | RETREATMENT | EPIDEMIOLOGY | LEDIPASVIR | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Young Adult | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Hepacivirus - isolation & purification | Administration, Oral | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Sulfonamides - therapeutic use | Isoquinolines - therapeutic use | Aged | Hepacivirus - classification | Isoquinolines - administration & dosage | Sulfonamides - administration & dosage | Hepatitis | Genotype & phenotype | Infections | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Viral hepatitis: towards the eradication of HCV and a cure for HBV
by Marcellin, Patrick
Liver International, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 5 - 6
GASTROENTEROLOGY & HEPATOLOGY | Disease Eradication - trends | Congresses as Topic | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Hepatitis C - epidemiology | Humans | Hepatitis B - drug therapy | Drug Therapy, Combination | Paris | Hepatitis C virus | Control | Hepatitis B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
by Bourlière, Marc, Dr and Bronowicki, Jean-Pierre, MD and de Ledinghen, Victor, MD and Hézode, Christophe, MD and Zoulim, Fabien, MD and Mathurin, Philippe, MD and Tran, Albert, MD and Larrey, Dominique G, MD and Ratziu, Vlad, MD and Alric, Laurent, MD and Hyland, Robert H, DPhil and Jiang, Deyuan, PhD and Doehle, Brian, PhD and Pang, Phillip S, MD and Symonds, William T, PharmD and Subramanian, G Mani, MD and McHutchison, John G, MD and Marcellin, Patrick, MD and Habersetzer, François, MD and Guyader, Dominique, MD and Grangé, Jean-Didier, MD and Loustaud-Ratti, Véronique, MD and Serfaty, Lawrence, MD and Metivier, Sophie, MD and Leroy, Vincent, MD and Abergel, Armand, MD and Pol, Stanislas, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 397 - 404
Summary Background Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but... 
Infectious Disease | SUSTAINED VIROLOGICAL RESPONSE | FIBROSIS | INFECTIOUS DISEASES | TREATMENT-NAIVE | TELAPREVIR | HEPATITIS-C VIRUS | PLUS SOFOSBUVIR | ACCESS PROGRAM | TREATMENT-EXPERIENCED PATIENTS | PEGYLATED INTERFERON | BOCEPREVIR | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Young Adult | Adult | Female | France | Placebos - administration & dosage | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Hepacivirus - classification | Care and treatment | Proteases | Clinical trials | Product development | Genetic aspects | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Ribavirin | Genotype & phenotype | Liver cancer | Interferon | Mortality | Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
by Bacon, Bruce R and Gordon, Stuart C and Lawitz, Eric and Marcellin, Patrick and Vierling, John M and Zeuzem, Stefan and Poordad, Fred and Goodman, Zachary D and Sings, Heather L and Boparai, Navdeep and Burroughs, Margaret and Brass, Clifford A and Albrecht, Janice K and Esteban, Rafael and HCV RESPOND2-Investigators and HCV RESPOND-2 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1207 - 1217
In this trial involving patients infected with hepatitis C virus (HCV) genotype 1 in whom previous treatment had failed, boceprevir plus peginterferon and... 
PROTEASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | INTERFERON | THERAPY | PEGINTERFERON ALPHA-2B | CHRONIC HEPATITIS-C | RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Recombinant Proteins | Polyethylene Glycols - therapeutic use | Viral Load | Serine Proteinase Inhibitors - therapeutic use | Serine Proteinase Inhibitors - adverse effects | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Anemia - chemically induced | Genotype | Logistic Models | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Proline - therapeutic use | Retreatment | Antiviral Agents - adverse effects | Proline - adverse effects | Hepatitis | Genotype & phenotype | Liver diseases | Human immunodeficiency virus--HIV | Investigations | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials
by Younossi, Zobair M and Stepanova, Maria and Marcellin, Patrick and Afdhal, Nezam and Kowdley, Kris V and Zeuzem, Stefan and Hunt, Sharon L
Hepatology, ISSN 0270-9139, 06/2015, Volume 61, Issue 6, pp. 1798 - 1808
Treatment with interferon (IFN) and ribavirin (RBV) significantly impairs quality of life and other patient‐reported outcomes (PROs). Patient experience with... 
UNITED-STATES | ALL-CAUSE | VIRUS-INFECTION | ANTIVIRAL TREATMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | WORK PRODUCTIVITY | HCV | QUALITY-OF-LIFE | NATURAL-HISTORY | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Fluorenes - therapeutic use | Male | Hepatitis C, Chronic - drug therapy | Uridine Monophosphate - analogs & derivatives | Quality of Life | Adult | Female | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
by Afdhal, Nezam and Zeuzem, Stefan and Kwo, Paul and Chojkier, Mario and Gitlin, Norman and Puoti, Massimo and Romero-Gomez, Manuel and Zarski, Jean-Pierre and Agarwal, Kosh and Buggisch, Peter and Foster, Graham R and Bräu, Norbert and Buti, Maria and Jacobson, Ira M and Subramanian, G. Mani and Ding, Xiao and Mo, Hongmei and Yang, Jenny C and Pang, Phillip S and Symonds, William T and McHutchison, John G and Muir, Andrew J and Mangia, Alessandra and Marcellin, Patrick and ION-1 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
In this trial, previously untreated patients with hepatitis C virus genotype 1 infection were randomly assigned to 12 or 24 weeks of ledipasvir and sofosbuvir,... 
MEDICINE, GENERAL & INTERNAL | TELAPREVIR | THERAPY | HEPATITIS | BOCEPREVIR | RIBAVIRIN | COMBINATION | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Young Adult | Aged, 80 and over | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Sofosbuvir | Headache | Chronic infection | Fatigue | Infections | Nausea | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Antiviral agents | Hepatitis C virus | Virus de l'hepatitis C | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B
by Kitrinos, Kathryn M and Corsa, Amoreena and Liu, Yang and Flaherty, John and Snow‐Lampart, Andrea and Marcellin, Patrick and Borroto‐Esoda, Katyna and Miller, Michael D
Hepatology, ISSN 0270-9139, 02/2014, Volume 59, Issue 2, pp. 434 - 442
One major challenge in the treatment of chronic hepatitis B is to maintain long‐term viral suppression without promoting the selection of drug‐resistant... 
NUCLEOTIDE ANALOGS | LAMIVUDINE | NUCLEOSIDE | ENTECAVIR | VIRUS | NAIVE PATIENTS | ADEFOVIR DIPIVOXIL | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | HBV | LONG-TERM EFFICACY | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Prevalence | Double-Blind Method | Antiviral Agents - therapeutic use | Humans | Genotype | Treatment Outcome | Adenine - pharmacology | Mutation - genetics | Hepatitis B virus - drug effects | Phenotype | Hepatitis B, Chronic - drug therapy | Phosphorous Acids - pharmacology | Adenine - therapeutic use | Phosphorous Acids - therapeutic use | Viremia - epidemiology | Drug Resistance, Viral - drug effects | Patient Compliance | DNA, Viral - genetics | Longitudinal Studies | Hepatitis | Drug therapy | Drug resistance | Patients | Hepatology | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights